



## ***Media Release***

**FOR IMMEDIATE RELEASE**

### ***Contact Serentis***

Julie Walters at Tudor Reilly

Tel: +44 (0) 1494 753 990

Mobile: +44 (0) 775 3626967

[julie.walters@tudor-reilly.com](mailto:julie.walters@tudor-reilly.com)

In the US:

Michele Parisi at Tudor Reilly

Tel: +1 925 864 5028

[michele.parisi@tudor-reilly.com](mailto:michele.parisi@tudor-reilly.com)

Tim Sharpington, CEO, Serentis

Tel: +44 (0) 1223 432500

[timsharpington@serentis-pharma.com](mailto:timsharpington@serentis-pharma.com)

Peter Keen, Corporate Development &  
Finance Director, Serentis

Tel: +44 (0) 1223 432500

[peterkeen@serentis-pharma.com](mailto:peterkeen@serentis-pharma.com)

### **Serentis appoints Dr Robert Tansley as Chief Medical Officer**

Cambridge, UK, 24 February, 2009 – Serentis, a privately owned biopharmaceutical company, today announced the appointment of Dr Robert Tansley as Chief Medical Officer.

Before joining Serentis, Robert was the Development & Medical Director of Sosei R&D. Previously, he served in a variety of senior roles in development and regulatory affairs at Sanofi, Roche, Arakis and as a Medical Assessor in the Licensing Division of the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

In addition to his medical degree from University College London, Robert has an M.Phil in Biostatistics from the University of Cambridge and an MBA from the London Business School.

Tim Sharpington, Serentis' Chief Executive Officer, commented "We are delighted to welcome Robert to Serentis. With the start of a more intense clinical development stage for Serentis, Robert's expertise in this area will be of great importance to the company".

### **About Serentis**

Serentis is a privately owned biopharmaceutical company founded in 2006 with the objective of developing a pipeline of innovative, proprietary products to address unmet medical needs.

The company's strategy is to establish a clinical-stage development pipeline and to move projects rapidly through proof-of-principle trials. The pipeline is sourced from in-house, low-risk research programmes and through licensing or acquisition of projects from external sources. The pipeline includes SRD441, a topical therapy with a new mode of action for the treatment of atopic dermatitis (AD) and SRD174, a topical treatment for pruritus (itch), a distressing symptom of AD.

For further information, visit [www.serentis-pharma.com](http://www.serentis-pharma.com)

ENDS